United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$260.51 USD
-1.89 (-0.72%)
Updated May 6, 2024 04:00 PM ET
After-Market: $260.31 -0.20 (-0.08%) 5:24 PM ET
2-Buy of 5 2
B Value B Growth A Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 121 - 140 ( 585 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso DPI/PAH & PH-ILD NDA Accepted Ahead of Schedule; PDUFA in October
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
First Patient Enrolled in Phase 3 TETON study of Tyvaso in IPF
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Sales Beat; NextGen Pipeline Continues to Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Sights on Treprostinil Market With Multifaceted Strategy in Place; PT Up to $248
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso DPI: NDA Submitted; Potential U.S. Approval Anticipated in Dec
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso PH-ILD Approval on Schedule, Launch Underway; PT to $276
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Pipeline Update: Trevyent® Discontinued, No Change to PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Year of Anticipated Launches Builds Pipeline From PAH and PH-ILD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Sales Beat & Cash Rich; Next: Tyvaso®/PH-ILD PDUFA in April
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Positive TYVASO DPI- Data; NDA Filing Anticipated in April With Priority Review
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L